PeptideDB

MIPS-521 1146188-19-3

MIPS-521 1146188-19-3

CAS No.: 1146188-19-3

MIPS521 is a positive allosteric modulator (PAM) of the adenosine receptor (A1AR). MIPS521 also has low allosteric affin
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

MIPS521 is a positive allosteric modulator (PAM) of the adenosine receptor (A1AR). MIPS521 also has low allosteric affinity for A1AR (pKB=4.95; KB=11 μM). MIPS521 displays pain-reducing effects in vivo by modulating elevated endogenous adenosine levels in the rat spinal cord.

Physicochemical Properties


Molecular Formula C19H10CLF6NOS
Molecular Weight 449.797223567963
Exact Mass 449.01
Elemental Analysis C, 50.74; H, 2.24; Cl, 7.88; F, 25.34; N, 3.11; O, 3.56; S, 7.13
CAS # 1146188-19-3
PubChem CID 25263603
Appearance Solid powder
LogP 7.2
Hydrogen Bond Donor Count 1
Hydrogen Bond Acceptor Count 9
Rotatable Bond Count 3
Heavy Atom Count 29
Complexity 570
Defined Atom Stereocenter Count 0
InChi Key IVHJBJJHYFIUOA-UHFFFAOYSA-N
InChi Code

InChI=1S/C19H10ClF6NOS/c20-13-3-1-9(2-4-13)16(28)15-14(8-29-17(15)27)10-5-11(18(21,22)23)7-12(6-10)19(24,25)26/h1-8H,27H2
Chemical Name

[2-amino-4-[3,5-bis(trifluoromethyl)phenyl]thiophen-3-yl]-(4-chlorophenyl)methanone
Synonyms

MIPS 521; MIPS-521; MIPS521
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets A1AR
ln Vitro MIPS521 (compound 13o) (3-10 μM) enhances R-PIA'scapacityto stimulate A1AR-mediated phosphorylation of ERK1/2[1].
MIPS521 (0.3-30 μM; pretreament for 10 min, co-treatment for 30 min) generates an expression of the percentage of the inhibition of 3 μM forskolin-mediated cAMP in CHO cells, which is a concentration-dependent potentiation of signaling by ADO in an inhibition of cAMP test[2].
ln Vivo MIPS521 (1-30 μg in 10 μL; intrathecal administration) promotes strong antinociception and reverses mechanical hyperalgesia in rats[2].
MIPS521 (10 μg in 10 μL; intrathecal administration) reduces spontaneous pain in a conditioned place preference model in a significant way[2].
MIPS521 (1-30 μg in 10 μL; intrathecal administration) has a pEC50 of 6.9 and lowers eEPSCs in the spinal cord of rats with nerve damage. Rats with nerve damage exhibit a significantly larger maximum MIPS521-induced decrease in synaptic current amplitude than do rats with sham surgery controls[2].
Animal Protocol Male and female Sprague-Dawley rats (7-12 weeks) were performed a partial nerve ligation (PNL) or sham surgery
1, 3, 10, 30 μg in 10 μL
Intrathecal administration
References

[1]. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. J Med Chem. 2009 Jul 23;52(14):4543-7.

[2]. Positive allosteric mechanisms of adenosine A 1 receptor-mediated analgesia. Nature. 2021 Sep;597(7877):571-576.


Solubility Data


Solubility (In Vitro) DMSO: 25~90 mg/mL (55.6~200.1 mM)
Ethanol: ~45 mg/mL
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2232 mL 11.1161 mL 22.2321 mL
5 mM 0.4446 mL 2.2232 mL 4.4464 mL
10 mM 0.2223 mL 1.1116 mL 2.2232 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.